NCT04653740Active, not recruiting
Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer
Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer (OMERIC): A Cohort Study
Source: ClinicalTrials.gov · Last updated 17 Sept 2026
Brief summary (registry, in English)
This is a monocentric cohort study, prospective and interventional with minimal risks and constraints for advanced breast cancer. The planned interventions are collection of biological samples at different times. The study will aim to do a descriptive analysis of omics profiles evolution (tumor, volatile organic components) over time, before and after disease progression under Palbociclib treatment with a clinical-biological database.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- First submitted
- 15 Sept 2020
- Start date
- Sept 2020
- Primary completion date
- Oct 2026
- Lead sponsor
- Centre Oscar Lambret
- Diseases
- Metastatic breast cancer
- NCT number
- NCT04653740
What you commit to
- Study type: Interventional
- Planned participants: 25
- From Sept 2020 to the primary completion date, Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Neoadjuvant or adjuvant treatment for localized breast cancer
- Metastatic breast cancer beyond the forth line
Other
- Impossibility to give informed consent (person deprived of liberty or under guardianship)
Who the study is looking for
- Women over 18 years old
- With histologically proven breast cancer, positives hormones receptors and negative HER2
- Advanced disease (metastases or non-resequable locoregional disease), from the 1st to the 4th line.
- With an indication for hormone therapy associated with the CDK4/6 inhibitor Palbociclib
- Agree to the sampling of the study
- Signed the informed consent form
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Oscar Lambret Coordinator of this site? Confirm its status | Lille | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.